Market Overview
Acute myeloid leukemia (AML) is a type of blood cancer occur in cells that turn into white blood cells. Acute myeloid leukemia starts in the bone marrow. Intrathecal chemotherapy is used to treat adult AML that spreads to the brain and spinal cord.

 

Arsenic trioxide and all-trans retinoic acid (ATRA) are anticancer drugs that kill the leukemia cells. These drugs are used in the treatment of a subtype of AML called acute promyelocytic leukemia.

 

Monoclonal antibody therapy is one type of targeted therapy, which are pipeline product for the treatment of adult AML. Monoclonal antibodies can identify substances on cancer cells or normal substances that may help cancer cells grow. These antibodies attach to the substances and kill the cancer cells, block their growth, or keep them from spreading.

 

The global acute myeloid leukemia therapeutics market size was worth $ XX billion in 2018 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period.

 

Market Dynamics

The increasing prevalence of acute myeloid leukemia (AML) is one of the factor fueling the global acute myeloid leukemia therapeutics market. 

 

For instance, according to American Cancer Society, in 2018, about 21,450 new cases of acute myeloid leukemia (AML) in the U.S.

 

According to American Cancer Society, in 2018, about 10,920 deaths from acute myeloid leukemia (AML).

 

In the U.S AML is one of the most common types of leukemia in adults. AML accounts for only about 1% of all cancers. Also,a according to Cancer Research UK, there are around 3,100 new acute myeloid leukaemia cases in the UK every year. Moreover, according to the Cancer Research UK, acute myeloid leukaemia accounts for less than 1% of all new cancer cases in UK.

 

Acute Myeloid Leukemia Therapeutics Market Segmentation Analysis

Based on chemotherapy drugs the global market for acute myeloid leukemia therapeutics is broadly segmented as by cytarabine, clolar, gleevac, sprycel, fludara, oncaspar, nelarabine, and treanda.

 

Currently cytarabine acute myeloid leukemia therapeutics is the dominant segment and it accounts for approximately XX% of the market, due to the increasing regulatory approval for cytarabine as a combination drug.

 

For instance, in November 2018, Pfizer, have received the U.S. Food and Drug Administration approval for Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

 

In November 2018, AbbVie, have received the U.S. Food and Drug Administration (FDA) approval for VENCLEXTA (venetoclax tablets) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

 

Geographical Share

The global Acute Myeloid Leukemia Therapeutics market is segmented into North America, Europe, Asia Pacific, South America and Middle East and Africa.

 

North America is dominating the global acute myeloid leukemia therapeutics market, due to the increasing regulatory approval for acute myeloid leukemia therapeutics.

 

For instance, in November 2018, Astellas Pharma Inc. have received the U.S. Food and Drug Administration (FDA) approved XOSPATA (generic name: gilteritinib) for the treatment of adult patients who have relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML). XOSPATA is an oral therapy and the first and only FLT3-targeting therapy to be approved.

 

In April 2017, Novartis, have received the US Food and Drug Administration (FDA) approval for Rydapt (midostaurin, formerly PKC412) for the treatment of acute myeloid leukemia (AML).

 

Competitive Trends

The increasing regulatory approval is one of the key factor driving the global acute myeloid leukemia therapeutics market.

 

For instance, in August 2017, Jazz Pharmaceuticals, have received the U.S. Food and Drug Administration approval for Vyxeos. Vyxeos is to treats adults with two types of acute myeloid leukemia (AML), newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is a fixed-combination of chemotherapy drugs daunorubicin and cytarabine.

 

In August 2017, Celgene Corporation and Agios Pharmaceuticals, Inc. have received approval for IDHIFA (enasidenib) from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2). IDHIFA, is an oral targeted inhibitor of the IDH2 enzyme.

 

The major players include Sunesis Pharmaceuticals, Celgene Corporation, Eisai Co. Ltd, Clavis Pharma, Cephalon Inc, Ambit Biosciences Corporation, Genzyme Corporation, Bristol Myers Squibb, Johnson and Johnson, Pfizer, Novartis, and Roche.

 

Why Purchase the Report?

  • Visualize the composition of the acute myeloid leukemia therapeutics market across each indication, in terms of pipeline drugs, chemotherapy drugs, and chemotherapy regimens, highlighting the key commercial assets and players.
  • Identify commercial opportunities in acute myeloid leukemia therapeutics market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of acute myeloid leukemia therapeutics market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players.

 

Target Audience:

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

 

1. Acute Myeloid Leukemia Therapeutics Market – Methodology and Scope

1.1. Research Methodology

1.2. Research Objective and Scope of the Report

2. Acute Myeloid Leukemia Therapeutics Market – Market Definition and Overview

3. Acute Myeloid Leukemia Therapeutics Market – Executive Summary

3.1. Market Snippet by Pipeline Drugs

3.2. Market Snippet by Chemotherapy Drugs

3.3. Market Snippet by Chemotherapy Regimens

3.4. Market Snippet by Region

3.5. DataM CLO Scenario

4. Acute Myeloid Leukemia Therapeutics Market – Market Dynamics

4.1. Market Impacting Factors

4.1.1. Drivers

4.1.1.1. Rising Acute Myeloid Leukemia Prevalence

4.1.1.2. Increasing regulatory approval

4.1.2. Restraints

4.1.2.1. Adverse effects of treatment

4.1.2.2. high cost of the therapeutic process

4.1.3. Opportunity

4.1.3.1. Increasing pipeline products

4.1.4. Impact Analysis

5. Acute Myeloid Leukemia Therapeutics Market – Industry Analysis

5.1. Porter's Five Forces Analysis

5.2. Supply Chain Analysis

5.3. Regulatory Analysis

5.4. Epidemiology

6. Acute Myeloid Leukemia Therapeutics Market – By Pipeline drugs

6.1. Bosutinib

6.2. Vidaza

6.3. Vosaroxin

6.4. Omapro

6.5. Quizartinib

6.6. Dacogen

6.7. Metabolic inhibitors         

7. Acute Myeloid Leukemia Therapeutics Market – By Chemotherapy Drugs

7.1. Cytarabine

7.2. Clolar

7.3. Gleevac

7.4. Sprycel

7.5. Fludara

7.6. Oncaspar

7.7. Nelarabine

7.8. Treanda

8. Acute Myeloid Leukemia Therapeutics Market – By Chemotherapy Regimens

8.1. Introduction

8.1.1. AVD regimen

8.1.2. DC regimen

8.1.3. VCD regimen

8.1.4. FC regimen

8.1.5. Hyper-CVAD regimen

8.1.6. FCR regimen

9. Acute Myeloid Leukemia Therapeutics Market – By Region

9.1. North America

9.1.1. U.S.

9.1.2. Canada

9.1.3. Mexico

9.2. Europe

9.2.1. Germany

9.2.2. U.K.

9.2.3. France

9.2.4. Italy

9.2.5. Spain

9.2.6. Rest of Europe

9.3. South America

9.3.1. Brazil

9.3.2. Argentina

9.3.3. Rest of South America

9.4. Asia Pacific

9.4.1. China

9.4.2. India

9.4.3. Japan

9.4.4. Australia

9.4.5. Rest of Asia Pacific

9.5. Middle East and Africa

10. Acute Myeloid Leukemia Therapeutics Market – Competitive Landscape

10.1. Competitive Scenario

10.2. Market Positioning/Share Analysis

10.3. Mergers and Acquisitions Analysis

11. Acute Myeloid Leukemia Therapeutics Market - Company Profiles

11.1. Sunesis Pharmaceuticals *

11.1.1. Company Overview

11.1.2. Product Portfolio and Description

11.1.3. Key Highlights

11.1.4. Financial Overview

11.2. Celgene Corporation

11.3. Eisai Co. Ltd

11.4. Clavis Pharma

11.5. Cephalon Inc

11.6. Ambit Biosciences Corporation

11.7. Genzyme Corporation

11.8. Bristol Myers Squibb

11.9. Johnson and Johnson

11.10. Pfizer

11.11. Novartis

11.12. Roche

12. Acute Myeloid Leukemia Therapeutics Market – Premium Insights

13. Acute Myeloid Leukemia Therapeutics Market – DataM

13.1. Appendix

13.2. About Us and Services

13.3. Contact Us

Table 1           Global Acute Myeloid Leukemia Therapeutics Market Value, By Pipeline drugs, 2018,2022 & 2026 ($ Million)

Table 2          Global Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Drugs, 2018, 2022 & 2026 ($ Million)

Table 3          Global Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Regimens, 2018, 2022 & 2026 ($ Million)

Table 4          Global Acute Myeloid Leukemia Therapeutics Market Value, By Region, 2018, 2022 & 2026 ($ Million)

Table 5          Global Acute Myeloid Leukemia Therapeutics Market Value, By Pipeline drugs, 2018, 2022 & 2026 ($ Million)

Table 6          Global Acute Myeloid Leukemia Therapeutics Market Value, By Pipeline drugs, 2017-2026 ($ Million)

Table 7          Global Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Drugs, 2018, 2022 & 2026 ($ Million)

Table 8          Global Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Drugs, 2017-2026 ($ Million)

Table 9          Global Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Regimens, 2018, 2022 & 2026 ($ Million)

Table 10        Global Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Regimens, 2017-2026 ($ Million)

Table 11         Global Acute Myeloid Leukemia Therapeutics Market Value, By Region, 2018, 2022 & 2026 ($ Million)

Table 12        Global Acute Myeloid Leukemia Therapeutics Market Value, By Region, 2017-2026 ($ Million)

Table 13        North America Acute Myeloid Leukemia Therapeutics Market Value, By Pipeline drugs, 2017-2026 ($ Million)

Table 14        North America Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Drugs, 2017-2026 ($ Million)

Table 15         North America Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Regimens, 2017-2026 ($ Million)

Table 16        North America Acute Myeloid Leukemia Therapeutics Market Value, By 0, 2017-2026 ($ Million)

Table 17         North America Acute Myeloid Leukemia Therapeutics Market Value, By 0, 2017-2026 ($ Million)

Table 18        North America Acute Myeloid Leukemia Therapeutics Market Value, By Country, 2017-2026 ($ Million)

Table 19        South America Acute Myeloid Leukemia Therapeutics Market Value, By Pipeline drugs, 2017-2026 ($ Million)

Table 20        South America Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Drugs, 2017-2026 ($ Million)

Table 21        South America Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Regimens, 2017-2026 ($ Million)

Table 22        South America Acute Myeloid Leukemia Therapeutics Market Value, By Country, 2017-2026 ($ Million)

Table 23        Europe Acute Myeloid Leukemia Therapeutics Market Value, By Pipeline drugs, 2017-2026 ($ Million)

Table 24        Europe Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Drugs, 2017-2026 ($ Million)

Table 25        Europe Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Regimens, 2017-2026 ($ Million)

Table 26        Europe Acute Myeloid Leukemia Therapeutics Market Value, By Country, 2017-2026 ($ Million)

Table 27        Asia-Pacific Acute Myeloid Leukemia Therapeutics Market Value, By Pipeline drugs, 2017-2026 ($ Million)

Table 28        Asia-Pacific Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Drugs, 2017-2026 ($ Million)

Table 29        Asia-Pacific Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Regimens, 2017-2026 ($ Million)

Table 30        Asia-Pacific Acute Myeloid Leukemia Therapeutics Market Value, By Country, 2017-2026 ($ Million)

Table 31        Middle East & Africa Acute Myeloid Leukemia Therapeutics Market Value, By Pipeline drugs, 2017-2026 ($ Million)

Table 32        Middle East & Africa Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Drugs, 2017-2026 ($ Million)

Table 33        Middle East & Africa Acute Myeloid Leukemia Therapeutics Market Value, By Chemotherapy Regimens, 2017-2026 ($ Million)

Table 34        Sunesis Pharmaceuticals: Overview

Table 35        Sunesis Pharmaceuticals: Product Portfolio

Table 36        Sunesis Pharmaceuticals: Key Developments

Table 37        Celgene Corporation: Overview

Table 38        Celgene Corporation: Product Portfolio

Table 39        Celgene Corporation: Key Developments

Table 40        Eisai Co. Ltd: Overview

Table 41        Eisai Co. Ltd: Product Portfolio

Table 42        Eisai Co. Ltd: Key Developments

Table 43        Clavis Pharma: Overview

Table 44        Clavis Pharma: Product Portfolio

Table 45        Clavis Pharma: Key Developments

Table 46        Cephalon Inc: Overview

Table 47        Cephalon Inc: Product Portfolio

Table 48        Cephalon Inc: Key Developments

Table 49        Ambit Biosciences Corporation: Overview

Table 50        Ambit Biosciences Corporation: Product Portfolio

Table 51         Ambit Biosciences Corporation: Key Developments

Table 52        Genzyme Corporation: Overview

Table 53        Genzyme Corporation: Product Portfolio

Table 54        Genzyme Corporation: Key Developments

Table 55        Bristol Myers Squibb: Overview

Table 56        Bristol Myers Squibb: Product Portfolio

Table 57        Bristol Myers Squibb: Key Developments

Table 58        Johnson and Johnson: Overview

Table 59        Johnson and Johnson: Product Portfolio

Table 60        Johnson and Johnson: Key Developments

Table 61        Pfizer: Overview

Table 62        Pfizer: Product Portfolio

Table 63        Pfizer: Key Developments

 

LIST OF FIGURES

 

Figure 1         Global Acute Myeloid Leukemia Therapeutics Market Share, By Pipeline drugs, 2018 & 2026 (%)

Figure 2        Global Acute Myeloid Leukemia Therapeutics Market Share, By Chemotherapy Drugs, 2018 & 2026 (%)

Figure 3        Global Acute Myeloid Leukemia Therapeutics Market Share, By Chemotherapy Regimens, 2018 & 2026 (%)

Figure 4        Global Acute Myeloid Leukemia Therapeutics Market Share, By Region, 2018 & 2026 (%)

Figure 5        Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 6        Global Acute Myeloid Leukemia Therapeutics Market Y-o-Y Growth, By Pipeline drugs, 2018-2026 (%)

Figure 7        Bosutinib: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 8        Vidaza: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 9        Vosaroxin: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 10      Omapro: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 11       Quizartinib: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 12      Dacogen: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 13      Metabolic inhibitors: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 14      Global Acute Myeloid Leukemia Therapeutics Market Y-o-Y Growth, By Chemotherapy Drugs, 2018-2026 (%)

Figure 15       Cytarabine: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 16      Clolar: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 17       Gleevac: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 18      Sprycel: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 19      Fludara: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 20      Oncaspar: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 21      Nelarabine: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 22      Treanda: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 23      Global Acute Myeloid Leukemia Therapeutics Market Y-o-Y Growth, By Chemotherapy Regimens, 2018-2026 (%)

Figure 24      AVD regimen: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 25      DC regimen: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 26      VCD regimen: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 27      FC regimen: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 28      Hyper-CVAD regimen: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 29      FCR regimen: Global Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 30      Global Acute Myeloid Leukemia Therapeutics Market Y-o-Y Growth, By 0, 2018-2026 (%)

Figure 31      Global Acute Myeloid Leukemia Therapeutics Market Y-o-Y Growth, By Region, 2018-2026 (%)

Figure 32      North America Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 33      North America Acute Myeloid Leukemia Therapeutics Market Share, By Pipeline drugs, 2018 & 2026 (%)

Figure 34      North America Acute Myeloid Leukemia Therapeutics Market Share, By Chemotherapy Drugs, 2018 & 2026 (%)

Figure 35      North America Acute Myeloid Leukemia Therapeutics Market Share, By Chemotherapy Regimens, 2018 & 2026 (%)

Figure 36      North America Acute Myeloid Leukemia Therapeutics Market Share, By Country, 2018 & 2026 (%)

Figure 37      South America Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 38      South America Acute Myeloid Leukemia Therapeutics Market Share, By Pipeline drugs, 2018 & 2026 (%)

Figure 39      South America Acute Myeloid Leukemia Therapeutics Market Share, By Chemotherapy Drugs, 2018 & 2026 (%)

Figure 40      South America Acute Myeloid Leukemia Therapeutics Market Share, By Chemotherapy Regimens, 2018 & 2026 (%)

Figure 41      South America Acute Myeloid Leukemia Therapeutics Market Share, By Country, 2018 & 2026 (%)

Figure 42      Europe Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 43      Europe Acute Myeloid Leukemia Therapeutics Market Share, By Pipeline drugs, 2018 & 2026 (%)

Figure 44      Europe Acute Myeloid Leukemia Therapeutics Market Share, By Chemotherapy Drugs, 2018 & 2026 (%)

Figure 45      Europe Acute Myeloid Leukemia Therapeutics Market Share, By Chemotherapy Regimens, 2018 & 2026 (%)

Figure 46      Europe Acute Myeloid Leukemia Therapeutics Market Share, By Country, 2018 & 2026 (%)

Figure 47      Asia-Pacific Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 48      Asia-Pacific Acute Myeloid Leukemia Therapeutics Market Share, By Pipeline drugs, 2018 & 2026 (%)

Figure 49      Asia-Pacific Acute Myeloid Leukemia Therapeutics Market Share, By Chemotherapy Drugs, 2018 & 2026 (%)

Figure 50      Asia-Pacific Acute Myeloid Leukemia Therapeutics Market Share, By Chemotherapy Regimens, 2018 & 2026 (%)

Figure 51       Asia-Pacific Acute Myeloid Leukemia Therapeutics Market Share, By Country, 2018 & 2026 (%)

Figure 52      Middle East & Africa Acute Myeloid Leukemia Therapeutics Market Value, 2017-2026 ($ Million)

Figure 53      Middle East & Africa Acute Myeloid Leukemia Therapeutics Market Share, By Pipeline drugs, 2018 & 2026 (%)

Figure 54      Middle East & Africa Acute Myeloid Leukemia Therapeutics Market Share, By Chemotherapy Drugs, 2018 & 2026 (%)

Figure 55      Middle East & Africa Acute Myeloid Leukemia Therapeutics Market Share, By Chemotherapy Regimens, 2018 & 2026 (%)

Figure 56      Sunesis Pharmaceuticals: Financials

Figure 57      Celgene Corporation: Financials

Figure 58      Eisai Co. Ltd: Financials

Figure 59      Clavis Pharma: Financials

Figure 60      Cephalon Inc: Financials

Figure 61      Ambit Biosciences Corporation: Financials

Figure 62      Genzyme Corporation: Financials

Figure 63      Bristol Myers Squibb: Financials

Figure 64      Johnson and Johnson: Financials

Figure 65      Pfizer: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report